Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Net Cash Flow: 2013-2024

Historic Net Cash Flow for Seres Therapeutics (MCRB) over the last 12 years, with Dec 2024 value amounting to -$96.7 million.

  • Seres Therapeutics' Net Cash Flow rose 151.25% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.4 million, marking a year-over-year increase of 79.89%. This contributed to the annual value of -$96.7 million for FY2024, which is 175.72% down from last year.
  • As of FY2024, Seres Therapeutics' Net Cash Flow stood at -$96.7 million, which was down 175.72% from -$35.1 million recorded in FY2023.
  • Seres Therapeutics' Net Cash Flow's 5-year high stood at $72.0 million during FY2021, with a 5-year trough of -$96.7 million in FY2024.
  • In the last 3 years, Seres Therapeutics' Net Cash Flow had a median value of -$35.1 million in 2023 and averaged -$49.5 million.
  • Per our database at Business Quant, Seres Therapeutics' Net Cash Flow surged by 344.74% in 2020 and then plummeted by 175.72% in 2024.
  • Yearly analysis of 5 years shows Seres Therapeutics' Net Cash Flow stood at $50.9 million in 2020, then skyrocketed by 41.30% to $72.0 million in 2021, then plummeted by 123.33% to -$16.8 million in 2022, then tumbled by 108.91% to -$35.1 million in 2023, then slumped by 175.72% to -$96.7 million in 2024.